Events2Join

Viking Therapeutics to Present Key NASH Drug Trial ...


News & Events - Viking Therapeutics

News & Events. Investors. << Back. Viking Therapeutics to Present Data from Phase 2b VOYAGE Study ... In a Phase 1b clinical trial in patients ...

Viking Therapeutics to Present Key NASH Drug Trial ... - Stock Titan

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® ...

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study ...

PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

... study drug. 1) Deemed by investigator as ... (NASH) and fibrosis, successfully achieving both the trial's primary and secondary endpoints.

Viking Therapeutics Reports Third Quarter 2024 Financial Results ...

Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLD ... Prepaid clinical trial and ...

Viking's MASH drug scores where Madrigal's didn't - Fierce Biotech

A key readout for VK2735 in obesity is expected any day now, according to William Blair. Viking Therapeutics nonalcoholic steatohepatitis (NASH) ...

Viking Therapeutics Announces Results from Phase 1b Clinical Trial ...

Significant reductions were observed in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids compared to placebo. Key findings ...

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

Treatment with the Ionis drug also achieved a key secondary endpoint of MASH resolution without worsening fibrosis. Viking Therapeutics, Inc.

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

... study drug. 1) Deemed by investigator as ... (NASH) and fibrosis, successfully achieving both the trial's primary and secondary endpoints.

NASH at Fatty Liver Foundation

Viking Therapeutics has been a key player in the development of novel therapeutics ... The VOYAGE study, a Phase 2b clinical trial, was initiated by Viking ...

Viking Therapeutics Reports Second Quarter 2024 Financial Results ...

... report the results from this trial later this year. Finally, at the ... Prepaid clinical trial and preclinical study costs. 3,323. 2,624.

A randomized, double-blind, placebo-controlled phase IIa trial of ...

In the most advanced stages, NASH may present as cryptogenic cirrhosis or ... Therapeutics, Poxel, Sagimet Biosciences, and Viking Therapeutics. He ...

Viking Therapeutics Stock Falls After Drug Study Report

The company tested its drug, dubbed VK2809, in patients with nonalcoholic steatohepatitis, or NASH. ... Madrigal Pharmaceuticals Clears Key ...

Emerging from the Shadows: A New Era for NASH - IQVIA

These NASH-specific complexities have profound implications for sponsors of clinical trials investigating. NASH drug candidates,12 including: • ...

Viking says biopsy data confirm MASH drug's benefit | BioPharma Dive

Viking Therapeutics reported one-year data from a trial of a drug to treat NASH on June 4, 2024. Dr_Microbe via Getty Images. Dive Brief: A ...

vktx-ex991_6.htm - SEC.gov

Enrollment Continues in Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH ... Strong balance sheet provides runway to complete multiple key ...

Current therapies and new developments in NASH - Gut

... drugs used to initiate therapy in more severe disease and oral drugs providing long-term maintenance therapy. Key histological endpoints for clinical trials ...

Madrigal Pharmaceuticals Breaks Through In NASH With Late ...

Madrigal's NASH drug hits the mark in late-stage trial ... key secondary endpoint in the Phase III MAESTRO-NASH biopsy trial.

Two Experimental Therapies Show Promise for NASH - Hep

Two different types of medication for non-alcoholic steatohepatitis (NASH) have recently demonstrated good activity in Phase II clinical trials.

Review Article Clinical Trial Landscape in NASH - ScienceDirect.com

Table 1 summarizes the current NAFLD/NASH therapies. Despite these advances ... Pharmaceuticals and Viking Therapeutics. RL has stock options in 89bio ...